Patents Examined by Rita Desai
  • Patent number: 9879003
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 30, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Nathanael Gray, Priscilla Yang, Qingsong Liu, Mélissanne de Wispelaere
  • Patent number: 9856254
    Abstract: Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: January 2, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Bryon A. Merrill, Chad A. Haraldson, Michael J. Rice, Tushar A. Kshirsagar, Philip D. Heppner, Joshua R. Wurst, Shri Niwas, Sarah J. Slania
  • Patent number: 9856257
    Abstract: The invention related to pyrazolonaphthyridinone derivatives of formula (I) to their preparation and to their therapeutic use as selective inhibitors of type 2 methionine aminopeptidase (hMETAP2).
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: January 2, 2018
    Assignee: SANOFI
    Inventors: Nathalie Guillo, Valérie Martin
  • Patent number: 9850246
    Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 26, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Frank Chen, Carmela Molinaro, W. Peter Wuelfing, Nobuyoshi Yasuda, Jianguo Yin, Yong-Li Zhong, Joseph Lynch, Teresa Andreani
  • Patent number: 9834541
    Abstract: The invention provides novel substituted 2-aminopyridine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: December 5, 2017
    Assignees: CANCER RESEARCH TECHNOLOGY LIMITED, MERCK PATENT GMBH
    Inventors: Kai Schiemann, Frank Stieber, Julian Blagg, Aurelie Mallinger, Dennis Waalboer, Christian Rink, Simon Ross Crumpler
  • Patent number: 9822116
    Abstract: This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations, intermediates useful in said process, and processes for preparing said intermediates; also disclosed is a process for removal of metals from N-heterocyclic carbine metal complexes.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 21, 2017
    Assignee: OPKO Health, Inc.
    Inventors: George G. Wu, Gerald Werne, Xiaoyong Fu, Robert K. Orr, Frank Xing Chen, Jian Cui, Victoria M. Sprague, Fucheng Zhang, Ji Xie, Liansheng Zeng, Louis Peter Castellanos, Yuyin Chen, Marc Poirier, Ingrid Mergelsberg
  • Patent number: 9822111
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 21, 2017
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike
  • Patent number: 9815831
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 14, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Patent number: 9809589
    Abstract: The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile of formula (1); a crystal form thereof, a preparation method for the crystal form, and the use of the crystal form in the preparation of drugs for the treatment and/or prevention of renal injury or cardiovascular diseases.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: November 7, 2017
    Assignee: KBP BIOSCIENCES CO., LTD.
    Inventors: Chen Jiang, Aichen Wang, Dedong Zhang
  • Patent number: 9809542
    Abstract: The invention relates to novel compounds of the formula (I) in which W, X, Y, Z, A and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or fungicides. Moreover, the invention relates to selectively herbicidal compositions comprising, firstly, the spiroheterocyclically substituted tetramic acid derivatives and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising in particular spiroheterocyclically substituted tetramic acid derivatives through the addition of ammonium or phosphonium salts and optionally penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or acaricides and/or fungicides and/or for preventing unwanted vegetation.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 7, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Reiner Fischer, Arnd Voerste, Isolde Häuser-Hahn, Stefan Lehr, Elmar Gatzweiler, Ulrich Görgens, Ines Heinemann
  • Patent number: 9802957
    Abstract: This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: October 31, 2017
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Yongzhong Wu, Zhongjiang Jia, Yingrui Dai
  • Patent number: 9796681
    Abstract: Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general formula I or a pharmaceutically acceptable salt thereof: wherein “” represents a single or double bond, R1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Ra is hydrogen, —CH2R2, R3, or —SO2R4; R2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4 is lower aliphatic, or substituted or unsubstituted aryl; and R5 is hydrogen, halogen, or lower aliphatic.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: October 24, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Patrick J. Pagano, Peter Wipf, Maria E. Cifuentes-Pagano, Erin M. Skoda
  • Patent number: 9795599
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 24, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jaroslaw Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Patent number: 9796713
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 24, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ivar M. McDonald, Richard E. Olson, Robert A. Mate
  • Patent number: 9790173
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 17, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen
  • Patent number: 9777003
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: October 3, 2017
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Lixin Shao, Haisheng Wang
  • Patent number: 9771365
    Abstract: A compound of the formula I wherein the substituents are as defined in claim 1, are useful as a pesticides.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 26, 2017
    Assignee: Syngenta Participations AG
    Inventors: Michel Muehlebach, Thomas Pitterna, Jerome Yves Cassayre, Andrew Edmunds, Camilla Corsi, Myriem El Qacemi, Roger Graham Hall, Andre Jeanguenat, Andre Stoller, Christopher Richard Godfrey, Jurgen Harry Schaetzer, Olivier Loiseleur, Peter Maienfisch, Neil Brian Carter
  • Patent number: 9765074
    Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: September 19, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Fa-Xiang Ding, Shuzhi Dong, Dipshikha Biswas, Haifeng Tang, Jinlong Jiang, Cangming Yang, Xin Gu
  • Patent number: 9765071
    Abstract: Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: September 19, 2017
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Larry R. Krepski, Joseph F. Dellaria, Jr., Daniel E. Duffy, Matthew R. Radmer, David T. Amos
  • Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal